Summary:
SAILING is an experimental HIV treatment from the new integrase inhibitor class of antiretrovirals. This trial is comparing it to raltegravir - the only other drug currently approved in this class.
Participants in the trial must have genotypic or phenotypic resistance to at least one member of each of at least two antiretroviral therapy (ART) drug classes.
Qualified Participants Must:
• Have you had resistance to two or more drugs during your HIV treatment?
If you are committed to exploring options, you may qualify to receive up to 48 weeks of investigational study treatment and study related care at no cost.
No insurance is required.
Qualified Participants May Receive:
- Study drug
- Study related physical exam and laboratory testing